Cyclooxygenase-2 inhibitors in human skeletal fracture healing.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 16539205.
- Also identified by DOI 10.3928/01477447-20060301-02.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This article identifies the underlying molecular events responsible for fracture nonunions in a subset of fracture patients. Expression profiling of fracture callus tissue from both uneventful fracture repair and nonunion outcomes showed a decrease of COX-2 expression and an inability to mount an immune response in nonunion fractures. Validation in vitro with Saos-2 osteoprogenitor cell lines showed a decrease in osteogenesis potential after the cells were treated with celecoxib, a COX-2 specific inhibitor and anti-inflammatory agent. This article recapitulates that an initial immune response is crucial to fracture healing and suggests limited usage of COX-2 inhibitors in patients with healing fractures.
Medical subject headings
- Cyclooxygenase 2
- Cyclooxygenase Inhibitors
- Fracture Healing
- Fractures, Ununited
- Membrane Proteins
- Pyrazoles
- Sulfonamides